Viridian Therapeutics, Inc.
veligrotug
thyroid eye disease (TED)
Resolved
7days ago
FDA decision · Jun 30, 2026
What's at stake
The FDA's approval decision on veligrotug for thyroid eye disease (TED) is due Jun 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 16h ago
“Viridian is prepared for the planned U.S. commercial launch for veligrotug, its lead program for TED. Viridian anticipates the veligrotug commercial and medical affairs infrastructure will support a potential elegrobart launch, if approved,”